SLC1A2 and Hyperammonemia: Hyperammonemia reduced the surface expression of GLAST and GLT-1 to 66 ± 6% (p < 0.01, Fig. 6c) and 38 ± 6% (p < 0.0001, Fig. 6d) of controls, respectively.